Andrew L. Kung
- Molecular Biology top 0.1%
- Oncology top 0.2%
- Cancer Research top 0.1%
- Hematology top 0.1%
- Immunology top 0.5%
- Co-authors
- David M. LivingstonRenee D. WrightJames E. BradnerGerhard WagnerGregory L. VerdineScott A. ArmstrongSteven W. SherwoodScott J. Rodig
- Topics
- Protein Degradation and Inhibitors (41 papers)Acute Myeloid Leukemia Research (38 papers)Cancer, Hypoxia, and Metabolism (31 papers)
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Andrew L. Kung
273 papers receiving 23.8k citations
Hit Papers
Peers
Comparison fields: 5 of 154
- Molecular Biology 16.6k
- Oncology 6.6k
- Cancer Research 4.6k
- Hematology 4.1k
- Immunology 2.9k
Countries citing papers authored by Andrew L. Kung
This map shows the geographic impact of Andrew L. Kung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew L. Kung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew L. Kung more than expected).
Fields of papers citing papers by Andrew L. Kung
This network shows the impact of papers produced by Andrew L. Kung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew L. Kung. The network helps show where Andrew L. Kung may publish in the future.
Co-authorship network of co-authors of Andrew L. Kung
This figure shows the co-authorship network connecting the top 25 collaborators of Andrew L. Kung. A scholar is included among the top collaborators of Andrew L. Kung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew L. Kung. Andrew L. Kung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 18 | |
| 3 | 60 | |
| 4 | 7 | |
| 5 | 81 | |
| 6 | 59 | |
| 7 | 98 | |
| 8 | 49 | |
| 9 | 17 | |
| 10 | 42 | |
| 11 | 51 | |
| 12 | Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibitionbreakdown → | 457 |
| 13 | 158 | |
| 14 | 46 | |
| 15 | 156 | |
| 16 | 12 | |
| 17 | 60 | |
| 18 | 66 | |
| 19 | 96 | |
| 20 | A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumorsbreakdown → | 511 |
About Andrew L. Kung
Andrew L. Kung is a scholar working on Hematology, Cancer Research and Oncology, having authored 285 papers that have together received 24.2k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (41 papers), Acute Myeloid Leukemia Research (38 papers) and Cancer, Hypoxia, and Metabolism (31 papers). The work is most often cited by research in Hematology (4.1k citations), Cancer Research (4.6k citations) and Molecular Biology (16.6k citations). Andrew L. Kung has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include David M. Livingston, Renee D. Wright, James E. Bradner, Gerhard Wagner, Gregory L. Verdine, Scott A. Armstrong, Steven W. Sherwood, Scott J. Rodig, Loren D. Walensky and Stanley J. Korsmeyer. Their work appears in journals such as Nature, Science and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.